Practice pearl: a novel use of rifampicin for treatment of carpal tunnel syndrome.
Namazi
Hamid
H
D002349:Carpal Tunnel Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D009842:Oligopeptides / Q000187:drug effects / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects / Q000378:metabolism; D000077293:Receptor, Transforming Growth Factor-beta Type I; D018125:Receptors, Transforming Growth Factor beta / Q000187:drug effects / Q000378:metabolism; D012293:Rifampin / Q000494:pharmacology* / Q000627:therapeutic use; D051899:Smad2 Protein / Q000037:antagonists & inhibitors / Q000378:metabolism; D051900:Smad3 Protein / Q000037:antagonists & inhibitors / Q000378:metabolism; D018808:Transcription Factor AP-1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors* / Q000276:immunology*
D007166:Immunosuppressive Agents; D016328:NF-kappa B; D019384:Nucleic Acid Synthesis Inhibitors; D009842:Oligopeptides; D018125:Receptors, Transforming Growth Factor beta; C497782:SMAD2 protein, human; C497790:SMAD3 protein, human; D051899:Smad2 Protein; D051900:Smad3 Protein; D018808:Transcription Factor AP-1; D016212:Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077293:Receptor, Transforming Growth Factor-beta Type I; C058504:goralatide; D012293:Rifampin